Stock Ratings | With potential for a 431% gain, HC Wainwright & Co maintained a "buy" rating on shares of Atossa Therapeutics (ATOS), and raised its price target from $7 to $25.
Atossa Therapeutics, Inc. ATOS | 4.98 4.79 | +3.32% -3.81% Pre |
Nkarta NKTX | 2.34 2.34 | +1.30% 0.00% Pre |
Beam Therapeutics BEAM | 26.33 26.84 | +3.50% +1.93% Pre |
Aligos Therapeutics, Inc. ALGS | 7.94 7.94 | -0.63% 0.00% Pre |
Fiscalnote Holdings, Inc. Class A NOTE | 0.22 0.22 | -8.18% 0.00% Pre |
The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.
Risk warning:
Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.
Today's key assessments and concerns
HC Wainwright & Co.: Maintaining a "buy" rating on Atossa Therapeutics ( Atossa Therapeutics, Inc.(ATOS.US) ), with a price target raised from $7 to $25.
Needham: Maintaining a "buy" rating on Nkarta Nkarta(NKTX.US) ) stock, while raising the price target from $10 to $11.
Citigroup: Maintaining its "buy" rating on BEAM ( Beam Therapeutics(BEAM.US) ) stock, while raising its price target from $64 to $68.
WestPark Capital: Initial rating for Aligos Therapeutics ( Aligos Therapeutics, Inc.(ALGS.US) ) at "Buy", with a target price of $48.
Ladenburg Thalmann: Maintaining a "buy" rating on FiscalNote Holdings ( Fiscalnote Holdings, Inc. Class A(NOTE.US) ), while lowering the price target from $11 to $9.75.
| The symbol | Classification | Target price | Current price | Percentage of potential increase/decrease | (Classification) Agency |
| Atossa Therapeutics, Inc.(ATOS.US) | to lift | $25.0 | $4.71 | 430.79% | HC Wainwright & Co. |
| Nkarta(NKTX.US) | to lift | $11.0 | $2.14 | 414.02% | Needham |
| Beam Therapeutics(BEAM.US) | to lift | $68.0 | $23.62 | 187.89% | Citigroup |
| Corcept Therapeutics Incorporated.(CORT.US) | to lift | $110.0 | $38.53 | 185.49% | Canaccord Genuity |
| Precigen Inc(PGEN.US) | to lift | $10.0 | $3.89 | 157.07% | HC Wainwright & Co. |
| Aligos Therapeutics, Inc.(ALGS.US) | Initial classification | $48.0 | $7.04 | 581.82% | WestPark Capital |
| Fiscalnote Holdings, Inc. Class A(NOTE.US) | cut | $9.75 | $0.531 | 1736.16% | Ladenburg Thalmann |
| Nasus Pharma Ltd.(NSRX.US) | cut | $18.0 | $2.4 | 650.0% | Citizens |
| Vertical Aerospace Ltd.(EVTL.US) | cut | $9.5 | $2.39 | 297.49% | Canaccord Genuity |
| COMPASS Pathways Plc Sponsored ADR(CMPS.US) | cut | $18.0 | $5.64 | 219.15% | Canaccord Genuity |
comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)
Lifting
Morgan Stanley: Maintaining an "underweight" rating on American Assets Trust ( American Assets Trust, Inc.(AAT.US) ), while raising the price target from $17 to $18.
Truist Securities: Upgraded its rating on Airbnb, Inc.(ABNB.US) ) to "Hold", raising its price target from $107 to $129.
Jefferies: Maintaining a "buy" rating on AAR CORP. ( AAR CORP.(AIR.US) ), while raising the price target from $135 to $150.
First Coverage
WestPark Capital: Initial rating for Aligos Therapeutics ( Aligos Therapeutics, Inc.(ALGS.US) ) at "Buy", with a target price of $48.
Needham: A preliminary rating of "buy" for Abercrombie & Fitch ( Abercrombie & Fitch Co. Class A(ANF.US) ) stock, with a price target of $108.
Ladenburg Thalmann: Initial rating for Apple Hospitality REIT ( Apple Hospitality REIT Inc(APLE.US) ) at "neutral", with a target price of $13.
reduction
TD Cowen: Maintains its "Buy" rating on Accelerant Holdings ( Accelerant Holdings Class A(ARX.US) ), while lowering its price target from $36 to $30.
Morgan Stanley: Downgraded AvalonBay Communities ( AvalonBay Communities, Inc.(AVB.US) ) to "Market-matched weight" with a price target of $208 to $203.
Susquehanna: Maintaining a "positive" rating on Alibaba ( Alibaba Group Holding Ltd. Sponsored ADR(BABA.US) ), while lowering the price target from $190 to $170.
Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk warning:
Investing involves risk, and securities prices can rise or fall, or even become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, and risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.